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A B S T R A C T
While the ApoE ε4 allele is a known risk factor for mild cognitive impairment (MCI) and Alzheimer's disease,
brain region speciﬁc eﬀects remain elusive. In this study, we investigate whether the ApoE ε4 allele exhibits
brain region speciﬁc eﬀects in longitudinal glucose uptake among patients with MCI from the Alzheimer's
Disease Neuroimaging Initiative (ADNI). Preprocessed FDG PET images, MRIs, and demographic information
were downloaded from the ADNI database. An iterative reblurred Van Cittertiteration method was used for
partial volume correction (PVC) on all PET images. Structural MRIs were used for PET spatial normalization and
region of interest (ROI) deﬁnition in standard space. Longitudinal changes in ROI FDG standardized uptake value
ratio (SUVR) relative to cerebellum in 24 ApoE ε4 carriers and 24 age-matched ApoE ε4 non-carriers were
measured for up to 84-months (median 72months, SD=11.2months) and compared using a generalized linear
mixed eﬀects model controlling for gender, education, baseline age, and follow-up period. Additionally, vox-
elwise analysis was performed by implementing a paired t-test comparing matched baseline and 72month FDG
SUVR images in ApoE carriers and non-carriers separately. Results with PVC were compared with ones from non-
PVC based analysis. After applying PVC, the superior fontal, parietal, lateral temporal, medial temporal, caudate,
thalamus, and post-cingulate, and amygdala regions had greater longitudinal decreases in FDG uptake in ApoE
ε4 carriers with MCI compared to non-carriers with MCI. Similar forebrain and limbic clusters were found
through voxelwise analysis. Compared to the PVC based analysis, fewer signiﬁcant ApoE-associated regions and
clusters were found in the non-PVC based PET analysis. Our ﬁndings suggest that the ApoE ε4 genotype is
associated with a longitudinal decline in glucose uptake in 8 forebrain and limbic brain regions in the context of
MCI. In conclusion, this 84-months longitudinal FDG PET study demonstrates a novel ApoE ε4-associated brain-
region speciﬁc glucose metabolism pattern in patients with MCI. Partial volume correction improved FDG PET
quantiﬁcation.
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1. Introduction
Alzheimer's disease (AD) is characterized by memory loss and cog-
nitive decline (Jahn, 2013; Rajan et al., 2015; Small et al., 2000). Pa-
thological signatures of AD include amyloid peptide plaques, neuroﬁ-
brillary tangles, and synaptic dysfunction (Mosconi et al., 2010;
Thambisetty et al., 2010a). Neuroimaging studies have established
glucose hypometabolism and bilateral temporoparietal hypoperfusion
in subjects who later develop AD (Lehtovirta et al., 1998; Mosconi et al.,
2004).
Previous studies have shown the dose dependent role of apolipo-
protein E (ApoE) ε4 allele as a risk factor for developing Alzheimer's
disease, increasing the risk of AD by 2.6 to 14.9 fold and lowering the
onset by 7 to 15 years (Farrer et al., 1997; Thambisetty et al., 2010a).
By age 85, the lifetime risk estimate of developing Alzheimer's Disease
Dementia (ADD) is 60–70% for ε4/ε4 homozygotes and 20–30% for ε4/
ε3 heterozygotes (ApoE carriers) (Genin et al., 2011). In comparison,
the lifetime risk for developing ADD by the age of 85 for ε3 / ε3 in-
dividuals (ApoE non-carriers) is only ~10%, suggesting that ApoE is
moderately penetrant with a semi-dominant inheritance pattern (Genin
et al., 2011). In the brain, ApoE is produced by non-neuronal cells,
including astroglia and microglia, and functions by delivering choles-
terol to neurons (Liu et al., 2013; Zhang et al., 2013). ApoE ε4, together
with ApoE ε2 and ε3, comprise the three major allelic forms of ApoE
each diﬀering at amino acid positions 112 and 158. In addition to its
known association with cognitive decline and Alzheimer's, including
recent GWAS studies identifying ApoE ε4 as the main genetic de-
terminant of Alzheimer's, polymorphic forms of ApoE ε4 have been
linked to diverse physiological consequences including atherosclerosis,
faster disease progression in multiple sclerosis, poor outcomes in trau-
matic brain injury, sleep apnea and a higher risk for type III hyperli-
poproteinemia (Breslow et al., 1982; Elias-Sonnenschein et al., 2011;
Feussner et al., 1998; Friedman et al., 1999; Kadotani et al., 2001;
Schmidt et al., 2002). Despite biochemical, transgenic mouse and
clinical studies oﬀering potential explanations for the role of ApoE ε4 in
AD progression, precise molecular mechanisms underlying ApoE ε4-
mediated AD risk remains elusive.
Pathological changes in patients who develop AD often start dec-
ades before the ﬁrst visible symptoms of AD. These changes can ﬁrst
present as mild cognitive impairment (MCI), a condition deﬁned as
cognitive decline above the age- and education-adjusted normal but
below the threshold for ADD (Petersen et al., 2001, 1999; Winblad
et al., 2004). Patients with MCI have an annual conversion rate to AD of
10–15%, in contrast to only 1–2% among healthy individuals (Bruscoli
and Lovestone, 2004; Chen et al., 2017; Petersen et al., 2001, 1999).
The presence of the ApoE ε4 allele increases the odds of converting
from amnestic MCI to ADD by 4.1 fold (95% CI: 1.2–13.6) (Petersen
et al., 2005; Scarabino et al., 2016). Yet in spite of these ﬁndings, little
is known about how the presence of the ApoE ε4 allele induces pa-
thological changes in the context of MCI. Given our existing knowledge
of the exquisite region-speciﬁc patterns of brain atrophy, glucose hy-
pometabolism, spread of tau and amyloid burden in AD progression, we
asked whether the ApoE ε4 allele, as the largest genetic determinant of
AD risk, also elicits similar brain-region speciﬁc changes in MCI which
often precedes Alzheimer's (Chan et al., 2003; Cope et al., 2018;
Drzezga et al., 2005; Grijalva-Eternod et al., 2012; Knopman et al.,
2014; Mecca et al., 2018; Misra et al., 2009; Mosconi et al., 2009).
Functional neuroimaging is a valuable non-invasive tool to monitor
disease progression and brain metabolic changes in various neurode-
generative disease, including AD, Parkinson's disease and HIV-asso-
ciated neurocognitive disorders (Chen et al., 2016; Dickens et al., 2017;
Gao et al., 2016; Niethammer et al., 2012). In particular, FDG-PET
imaging allows for the characterization of ApoE ε4-mediated pheno-
typic changes in AD and MCI, including its association with glucose
hypometabolism (Rosén et al., 2013). Cross sectional studies including
work by Reiman et al. have used FDG imaging to establish the dose-
dependent eﬀect of ApoE ε4 on hypometabolism in non-demented
adults (Reiman et al., 1996). Longitudinal studies such as work by
Thambisetty et al. used oxygen-15 PET to compare changes in cerebral
blood ﬂow in 29 non-demented ApoE ε4 carriers and 65 non-carriers
(Thambisetty et al., 2010a). They found greater longitudinal decline in
cerebral blood ﬂow in ApoE ε4 carriers compared to non-carriers in the
temporal, parietal, and frontal cortices. While these studies are im-
portant in establishing the association of the ApoE ε4 allele with in-
creased glucose hypometabolism, these studies were performed in the
context of normal aging.
These existing studies, including work by Thambisetty and Reiman,
have helped to show ApoE ε4 dose-dependent associations between
cerebral blood ﬂow decline and hypometabolism, both validated
readouts of AD (Reiman et al., 1996; Thambisetty et al., 2010a).
However, there exists a clear lack of> 4 years longitudinal FDG stu-
dies, which are critical for studying the role of ApoE ε4 in increasing the
risk of disease over time. In contrast to previous studies, a up to
84month (median 72month) follow up period was used in the present
study with partial volume correction (PVC) to minimize inaccuracies in
PET measurement due to changes in tissue volume or low spatial re-
solution. Partial volume eﬀect is particularly a concern in small brain
regions or in longitudinal studies in which atrophy can lead to an un-
derestimation or overestimation of the true changes in quantitative PET
(Jonasson et al., 2017). Several recent analyses have highlighted the
importance of correcting for partial volume eﬀects in longitudinal brain
PET studies (Dukart and Bertolino, 2014; Fouquet et al., 2009). In the
present study, we sought to characterize regional diﬀerences in glucose
metabolism over time between ApoE ε4 carriers and non-carriers with
MCI after PVC correction and compared these results with non-PVC
analysis. Speciﬁcally, we investigated regional associations between the
ApoE ε4 genotype and longitudinal changes in glucose uptake, mea-
sured using FDG PET, over a median 72-month follow-up period in 48
subjects with MCI (24 ApoE ε4 carriers and 24 non-carriers) from the
Alzheimer's Disease Neuroimaging Initiative (ADNI). We identiﬁed a
novel ApoE ε4–dependent longitudinal pattern of glucose hypometa-
bolism in MCI patients.
2. Methods
2.1. Subjects
We initially queried the ADNI 1,2, and GO databases for individuals
with at least a 48-month follow-up and FDG-PET and MRI data at each
study visit. This query was performed for a previous study conducted in
our group involving healthy controls and MCI individuals (Chen et al.,
2016). From this cohort, we selected all available MCI individuals with
FDG-PET and MRI at each scanning visit.
Consent was obtained from all study participants prior to the start of
the study. The study was conducted with Institutional Review Board
approval. We followed exclusion criteria determined by ADNI.
Speciﬁcally, subjects with neurological disease other than Alzheimer's,
including Parkinson's, multi-infarct dementia, Huntington's, normal
pressure hydrocephalus, brain tumor, progressive supranuclear palsy,
history of seizure, subdural hematoma, multiple sclerosis, history of
head trauma, and known brain structural abnormalities, were excluded
from our study. Additionally, subjects with evidence of infection, focal
lesions, or infarction on MRI were excluded. Individuals with pace-
makers, heart valve, or other foreign objects/implants in the body were
excluded. Patients with history of major depression, bipolar disorder,
schizophrenia, alcohol or substance abuse or those that are currently
using psychoactive medications were excluded.
At baseline, all MCI subjects had a subjective memory concern re-
ported by a clinician and abnormal memory function on the education-
adjusted Logical Memory II subscale. All MCI subjects were required to
have a clinical dementia rating of 0.5 or higher. Further, all MCI sub-
jects were deemed to have cognitive and functional performance that
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was suﬃciently intact to not merit a diagnosis of ADD by the site
physician.
A complete list of ADNI exclusion/inclusion procedures can be
found at https://adni.loni.usc.edu/wp-content/uploads/2008/07/
adni2-procedures-manual.pdf
All data were downloaded from the ADNI clinical data repository
(http://www.loni.ucla.edu/ADNI/). ADNI was launched in 2003 as a
public-private consortium. Informed consent was obtained by all study
participants at the time of enrollment for imaging data, genetic sample
collection and clinical questionnaires. The primary goal of ADNI is to
test whether serial MRI, PET, other biological markers, and clinical and
neuropsychological assessments can be combined to measure the pro-
gression of MCI and early AD.
2.2. ApoE genotyping
Peripheral blood (10mL) was collected from study participants to
be used for ApoE ε4 genotyping. Restriction enzyme isoform geno-
typing was used on DNA extracts to test for the presence of the ApoE ε4
genotype, as described previously (Hixson and Vernier, 1990). ApoE ε4
carriers (n=24) were deﬁned as individuals with at least one ε4 allele
(either ε4/ ε4, ε4/ ε3 or ε4/ ε2). Non-carriers (n=24) were deﬁned as
individuals with no ε4 allele.
2.3. Neuropsychological testing
The Neuropsychiatric Inventory questionnaire (Kaufer et al., 2000),
Global Clinical Dementia Rating (Hughes et al., 1982), Mini-Mental
State Examination (Pangman et al., 2000), Functional Assessment
Questionnaire (Pfeﬀer et al., 1982), Alzheimer's Disease Assessment
Scale and Geriatric Depression Scale (Pangman et al., 2000) were ad-
ministered during each scanning visit to assess cognitive decline that
can accompany Alzheimer's disease.
2.4. MRI and PET acquisition and processing
T1-weighted MRI, and pre-processed FDG PET images were down-
loaded from http://adni.loni.usc.edu/. Detailed methods in FDG PET
and MRI imaging and collection can be found at http://adni.loni.usc.
edu/methods-/pet-analysis/pre-processing. Before downloading the
images, the PET images were aligned, averaged, reoriented and then
interpolated into a standard image and voxel size (image volume
160×160×96, 1.5×1.5×1.5mm in x, y, z), and smoothed to a
uniform resolution of 8mm in full width at half maximum (FWHM) by
ADNI (Drzezga et al., 2005).
The downloaded PET images were then further processed using
Statistical Parametric Mapping software (SPM12, Wellcome
Department of Imaging Neuroscience, London, United Kingdom) and
MATLAB (The MathWorks Inc.). All preprocessed PET images after PVC
were coregistered to structural MRI images acquired at each follow up.
The MRI images were normalized to standard Montreal Neurologic
Institute (MNI) space using SPM12 and the VBM8 toolbox with a MRI
template (image volume: 121× 145×121, voxel size: 1.5× 1.5×15
mm in x, y, z). Transformation parameters determined by MRI spatial
normalization were then applied to the coregistered PET images for PET
spatial normalization. A total of 25 regions of interest (ROIs) including
cerebellum gray matter for reference tissue were manually drawn on
the MRI template using PMOD software (PMOD Technologies Ltd.,
Zürich, Switzerland) in standard MNI space. These tracer- and study-
speciﬁc ROIs have been described in our previous studies (Chen et al.,
2016; Gao et al., 2016; Gottesman et al., 2016; Resnick et al., 2010;
Zhou et al., 2007). A global cortex was deﬁned as a union of the orbital
frontal, prefrontal, superior frontal, lateral temporal, parietal, posterior
precuneus, occipital, anterior cingulate, and posterior cingulate. Stan-
dard uptake value ratio (SUVR) images relative to the cerebellum were
produced. A summary of ROIs imposed over a MRI in standard space is
presented in Supplementary Fig. 2. ROI SUVRs were obtained by ap-
plying ROIs to SUVR images in the MNI space.
PVC was applied to the preprocessed PET images to correct or
minimize potential underestimation in PET measurements due to low
image resolution, especially for small tissues such as the amygdala and
caudate. In brief, an iterative reblurred Van Cittertiteration method was
used for PVC on the mean images, where a 3-D Gaussian kernel of 8mm
FWHM was used for spatial smoothing function h, step length α=1.5,
and the iteration was stopped if relative percent change of PVC
images< 1% (Tohka and Reilhac, 2008).
For comparison purposes, the above image processing including
MRI-PET coregistration and spatial normalization, and ROI SUVR cal-
culation were also applied to the downloaded preprocessed FDG PET
images directly without PVC.
2.5. PET statistical analysis
ROI-based longitudinal changes in glucose uptake in ApoE ε4 car-
riers and non-carriers were evaluated by ﬁtting a linear mixed-eﬀects
model in R (R version: 3.1.1; www.r-project.org). Each subject's sex,
educational level, baseline age, follow-up period, and ApoE ε4 carrier
status by time interaction (ApoE:time) were included as ﬁxed eﬀects.
Subject ID was included as a random eﬀect. The generalized linear
mixed model was ﬁt for each ROI FDG SUVR and the ApoE:time term
was evaluated to identify regions with signiﬁcantly diﬀerent FDG up-
take over time between ApoE ε4 carriers and non-carriers. FDG at 0, 6,
12, 18, 24, 36, 48, 60, 72, 84months was included for a median follow-
up time of 72months.
Considering the increased variance in voxelwise SUVR measure-
ments compared to ROI-based SUVRs, we implemented a paired t-test to
increase statistical power in our voxelwise analyses. Speciﬁcally, we
implemented a paired t-test comparing matched 72months scans to
baseline scans using SPM12 (cluster level FWER<0.05; uncorrected
voxel p < .001) separately for ApoE ε4 carriers and non-carriers
(Thambisetty et al., 2010a, 2010b). The paired t-test design (in which
we could compare two timepoints) also helped avoid confounding re-
lated to inter-subject variation. 72months and baseline scans were
chosen to attain a follow-up period of 72months and remain consistent
with the median follow-up time of 72months used for the ROI-based
analysis. Cluster extents for ApoE ε4 carriers and non-carriers were 135
voxels and 85 voxels, respectively. Voxels were assigned anatomical
regions and Brodmann areas using Talairach Client (v2.4.3; talairach.
org).
2.6. Data availability
All datasets used during the current study are available in the ADNI
repository, adni.loni.usc.edu. Refer to Supplementary Table 1 for a list
of ADNI subjects used in this study.
3. Results
3.1. Participant characteristics and longitudinal changes in
neuropsychological performance
Following our selection criteria, we ended up with 24 ApoE ε4
carriers and 24 ApoE ε4 non-carriers with mild cognitive impairment
(MCI) ranging from 55 to 85 years of age. All subjects underwent FDG
PET scanning, structural MRI, and neuropsychological testing for a
median follow-up period of 72months (mean: 71.3months, standard
deviation (SD): 11.2 months; range: 48–84months). The mean number
of scans per participant was 7.5 (SD: 0.7 scans, range: 6–9 scans). The
average time interval between follow-up scans was 10.9months
(SD=1.3months). Table S1 summarizes which scans were available
for each participant. Statistical analysis showed no signiﬁcant diﬀer-
ences between the ApoE ε4 carriers and non-carriers in age, sex
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distribution, and education level at baseline (p: 0.12–0.90) (Table 1).
No statistically signiﬁcant diﬀerences were detected between carriers
and non-carriers at baseline in any neuropsychological tests (p:
0.18–0.99).
ApoE ε4 carriers had signiﬁcantly greater cognitive decline com-
pared to non-carriers over the follow-up period. Speciﬁcally, we ﬁt a
linear mixed eﬀects model with cognitive test score for each subject at
each timepoint as an outcome. Age at baseline, years of education, sex
and ApoE:time interaction were included as covariates. We tested the
eﬀect of ApoE ε4 allele on cognitive decline in our study cohort by
assessing the signiﬁcance of ApoE:time interaction term and found that
ApoE ε4 carriers exhibit signiﬁcantly greater declines in MMSE, FAQ,
CDR, GDS, and ADAS-cog11 and ADAS-cog13 compared to ApoE ε4
non-carriers over the study period (p < .05). We found no signiﬁcant
diﬀerence in longitudinal decline in NPIQ score between carriers and
non-carriers.
We also compared the diagnosis status (ADD or MCI) of the study
participants at baseline and last follow-up to see if there were diﬀer-
ences in the proportion of ApoE carriers and non-carriers that converted
to ADD. Among the ApoE ε4 carriers included in the study, at the last
follow-up, 13 of 24 ApoE ε4 carriers had converted to ADD. There were
also 24 APOE ε4 non-carriers scanned at baseline; at the last follow-up 9
of these 24 ApoE ε4 non-carriers had converted to ADD. The diﬀerence
in the rates of conversion to ADD between ApoE ε4 carriers and ApoE ε4
non-carriers were near-signiﬁcant (p= .123; one-tailed chi-square
test).
We then potted a Kaplan-Meier survival curve (Supplementary
Fig. 1) showing the conversion over time in ApoE ε4 carriers and
noncarriers. Survival was deﬁned as not converting to ADD. Individuals
that left the study or died before the last follow up were marked as
censored. The survival curve shows a cumulative survival of 37% (CI:
21% - 65%) for ApoE ε4 carriers and 57% (CI: 40% - 81%) for non-
carriers at the end of the follow-up period. This analysis indicates a non-
signiﬁcant trend (p= .17; Fleming-Harrington test) towards the APOE
carriers having an increased progression to ADD within the follow up
period, consistent with existing studies (Moreno-Grau et al., 2017;
Mosconi et al., 2004).
3.2. Longitudinal ROI-based FDG SUVR
Longitudinal ROI FDG SUVR in ApoE ε4 carriers vs non-carriers was
evaluated over a longitudinal follow-up (median= 72months) interval
using a generalized linear mixed eﬀects model controlling for educa-
tional level, time of scan, baseline age, and gender. We found ROIs of
the superior frontal cortex, amygdala, caudate, parietal cortex, pos-
terior cingulate, lateral temporal and medial temporal and thalamic
brain regions had signiﬁcantly greater longitudinal decreases in FDG
uptake in ApoE ε4 carriers compared to non-carriers for PVC based
SUVRs (ApoE:time coeﬃcient < 0; p < .05; Table 2). The superior
frontal and amygdala failed to reach signiﬁcance for non-PVC based
SUVRs. The partial volume eﬀects on the longitudinal FDG PET SUVR
measurements are demonstrated in Fig. 1 using the superior frontal
ROI. It clearly shows that the PVC increased contrast in longitudinal
FDG ROI SUVR between ApoE ε4 carriers and non-carriers. Fig. 1 also
shows an interaction eﬀect between ApoE ε4 carrier status and follow-
up time and conﬁrms the results of the generalized linear mixed-eﬀects
model.
3.3. FDG SUVR image SPM analysis
Voxel-wise FDG SUVR in ApoE ε4 carriers and non-carriers was
evaluated separately using a paired t-test to compare 72month scans
with 0month (baseline) scans. In ApoE ε4 carriers after PVC, 23 clusters
corresponding to voxels in the frontal, temporal gyrus, precuneus, and
anterior cingulate, posterior cingulate, caudate, thalamus, insula, and
parahippocampal gyrus (cluster-level FWER p < .05; peak-level un-
adjusted p < .001; Table 3, Figs. 2, 3) exhibit signiﬁcantly decreased
FDG uptake at 72months compared to 0months. In contrast, in ApoE ε4
noncarriers after PVC, 4 clusters in the medial temporal, inferior tem-
poral cortex, precuneus and posterior cingulate exhibited signiﬁcantly
decreased FDG uptake at 72months compared to 0months (cluster-
level FWER p < .05; peak-level unadjusted p < .001; Table 3, Figs. 2,
3). These results are broadly replicated at the individual level using two
representative ApoE ε4 carriers and two ApoE ε4 non-carriers in Fig. 2.
It clearly demonstrates a hypometabolic pattern in the parietal, tem-
poral, frontal, thalamus regions in the two ApoE ε4 carriers. Mean-
while, we observe minimal hypometabolic change in the two ApoE ε4
non-carriers. Voxel wise statistical results showing voxels with sig-
niﬁcant longitudinal decline in ApoE ε4 carriers and non-carriers are
shown in Fig. 3. These voxelwise results indicate that ApoE ε4 carriers
exhibit greater longitudinal decreases in FDG uptake in the frontal and
parietal cortices, cingulate, striatal, limbic regions and support the re-
sults of our ROI-based linear mixed-eﬀects analysis in which we con-
sidered FDG at 0, 6, 12, 18, 24, 36, 48, 60, 72, 84months.
Notably, in the non-PVC SUVR image-based SPM analysis, 14 clus-
ters exhibit signiﬁcantly decreased FDG uptake at 72months compared
to 0months among ApoE ε4 carriers No signiﬁcant clusters were de-
tected among ApoE ε4 non-carriers. In order to create an anatomical
visualization of the eﬀects of PVC on spatial resolution and image
contrast, we displayed one representative ApoE ε4 carrier and one ApoE
Table 1
Demographic and statistics of neuropsychological performance at baseline for
APOE ε4 carriers and non-carriers.
Baseline participant characteristics (n=48)
ApoE ε4
carrier
(n=24)
ApoE ε4 non-
carrier (n=24)
P valuea
Mean (Min,
Max, SD)
Mean
(Min, Max, SD)
Number of ε4ε4 / ε4ε3/ ε4ε2
in ApoE ε4 carriers
6/16/02
Number of ε3ε3 / ε3ε2/ in
ApoE ε4 non-carriers
24/0/0
Male / Female 18/6 16/8 0.53
Age 71.9
(55.3, 84,1.5)
75.6
(61.6, 85.4, 1.4)
0.12
Education years 15.6
(8, 20, 0.6)
15.1
(12, 20,0.6)
0.81
ADAS-cog TOTAL11b 9.9
(5.3, 20.3 0.8)
9.4
(5, 18, 0.7)
0.62
ADAS-cog TOTALMODb 16.6
(8.3, 28.3, 1.1)
14.9
(9, 29, 1.4)
0.36
MMSEc 27.9
(24, 30, 0.3)
27.5
(24, 30, 0.3)
0.43
Global CDRd 0.5
(0.5, 0.5, 0)
0.5
(0.5, 0.5 0)
0.33
NPIQ Total Scoree 2.4
(0, 17, 0.7)
1.5
(0, 6, 0.3)
0.3
FAQ Total Scoref 3.0
(0, 9, 0.6)
2.6
(0, 13, 0.7)
0.69
GDS Total Scoreg 1.3
(0, 5, 0.3)
1.6
(0, 5, 0.3)
0.35
a P value represents statistical signiﬁcance level of diﬀerence in ApoE ε4
carriers vs non-carriers.
b ADAS-Cog TOTAL 11 contains eleven items on the Alzheimers's Diseaes
Assessment Scale including word recall, recognition, naming, etc. (range 0–70)
and ADAS-Cog Total Mod includes all the eleven items plus delayed word recall
and number cancellation (range 0–85).
c MMSE refers to the Mini-Mental State Examination.
d Global CDR refers to the Global Clinical Dementia Rating.
e NPIQ refers to the Neuropsychiatric Inventory questionnaire.
f FAQ refers to Functional Assessment Questionnaire.
g GDS refers to the Geriatric Depression Scale.
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ε4 non-carrier with and without PVC in Fig. 4. At the individual level,
Fig. 4 clearly demonstrates an increase in spatial resolution and con-
trast after PVC. The results at the individual level are quite consistent
when averaged over our studied population as illustrated in Fig. 5:
mean FDG SUVR images at 0months and 72months averaged over all
ApoE ε4 carriers and non-carriers.
We also compared baseline FDG-PET scans between Apoe ε4 carriers
and non-carriers to understand basal diﬀerences in FDG. We found no
signiﬁcant ApoE-associated voxels in either PVC or non-PVC data (two-
sample t-test, cluster level FWER<0.05; uncorrected voxel p < .001).
4. Discussion
In this study, we attempt to evaluate the spatial eﬀects of the ApoE
ɛ4 allele on metabolic changes in MCI measured by FDG PET using a
PVC-based method to accurately assess longitudinal changes in FDG. In
our sample of ApoE ɛ4 carriers and non-carriers with MCI, there was a
clear longitudinal metabolic pattern in several brain regions that dif-
fered between ApoE ɛ4 carriers and ApoE ɛ4 non-carriers. Speciﬁcally,
we found that the parietal cortex, temporal cortex, posterior cingulate,
amygdala, caudate, and thalamic regions show greater longitudinal
decreases in FDG tracer uptake in ApoE ε4 carriers compared to non-
carriers in MCI patients. Importantly, these ﬁndings are unlikely to
reﬂect diﬀerences in cognitive status, baseline age, education, follow-
Table 2
ROI-based Analysis: Regions with Greater Decrease in ApoE ε4 Carriers vs. Non-Carriers in 72-month Longitudinal FDG PET Study Among Patients with MCI.
PVC No PVC
Pa Mean Baseline Scan
(SEM)
Mean Percent Change Over Follow-Up
Interval (SEM)b
Pa Mean Baseline Scan
(SEM)
Mean Percent Change Over Follow-Up
Interval (SEM)b
Region Carrier Non- carrier Carrier Non- carrier Carrier Non- carrier Carrier Non- carrier
Superior Frontal 0.03 1.139 1.184 −0.58 −0.132 0.065 1.102 1.141 −0.503 −0.173
0.025 0.03 0.284 0.305 0.024 0.028 0.275 0.289
Lateral Temporal < 0.001 0.971 1.009 −1.044 −0.363 0.001 0.937 0.975 −0.989 −0.413
0.017 0.018 0.355 0.267 0.016 0.017 0.316 0.262
Medial Temporal 0.02 0.755 0.78 −0.824 −0.22 0.045 0.767 0.795 −0.929 −0.405
0.017 0.016 0.335 0.421 0.017 0.017 0.335 0.396
Parietal < 0.001 1.034 1.054 −1.5 −0.31 <0.001 1.017 1.045 −1.353 −0.332
0.019 0.024 0.353 0.344 0.019 0.024 0.328 0.326
Posterior Cingulate 0.002 1.231 1.287 −1.266 −0.632 0.037 1.28 1.346 −1.036 −0.642
0.029 0.031 0.304 0.263 0.03 0.032 0.288 0.259
Amygdala 0.02 0.726 0.751 −0.428 0.291 0.094 0.77 0.806 −0.575 −0.121
0.019 0.015 0.337 0.354 0.017 0.016 0.325 0.315
Caudate < 0.001 1.104 1.072 −1.686 −0.055 <0.001 0.947 0.935 −1.308 −0.167
0.044 0.051 0.584 0.709 0.034 0.038 0.479 0.561
Thalamus 0.002 1.363 1.344 −0.803 1.152 0.003 1.196 1.19 −0.637 0.651
0.027 0.067 0.665 0.582 0.026 0.049 0.481 0.525
a P value represents statistical signiﬁcance level of diﬀerence in APOE carriers versus non-carriers adjusted for sex, education level, baseline age using a general
linear mixed eﬀects model.
b Percent decrease was averaged over all follow-up intervals for all participants to determine a mean percent decrease in FDG.
Fig. 1. ROI-based analysis: Superior frontal cortex FDG SUVR dynamics in ApoE ε4 Carriers and Noncarriers with Mild Cognitive Impairment. Graphical re-
presentation of longitudinal FDG SUVR in ApoE ε4 carriers and non-carriers for PVC and non-PVC PET. FDG SUVR in the superior frontal cortex is plotted over time
to show diﬀerences between ApoE ε4 carriers and non-carriers over the follow-up period. Diﬀerences in rates of FDG decline between ApoE ε4 carriers and non-
carriers were assessed by ﬁtting a linear mixed eﬀects model to the ROI SUVRs, controlling for baseline age, education, follow-up interval and sex. (Table 2). The
graph visually demonstrates an interaction eﬀect between ApoE ε4 carrier status and follow-up time; ApoE ε4 carriers exhibit greater longitudinal decreases in
superior frontal FDG compared to non-carriers. Due to partial volume eﬀects, the contrast of longitudinal SUVRs between ApoE ε4 carriers and noncarriers was
reduced in non-PVC PET data. Note, 96months data is not shown because there were no ApoE ε4 carriers scans at this timepoint.
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Table 3
Voxelwise analysis: Voxels with Signiﬁcant Decrease at 72months compared to Baseline Among ApoE ε4 carriers with MCI.
Cluster level Peak level
MNI Coordinatesb
Corrected P valuea Cluster size (No. of Voxels) Z P value Cohen's D x y z Regionc Brodmann Area
ApoE ε4 Carrier SUVR at 72month < SUVR at 0month
0 196 5.33 < 0.001 1.09 −24 −70 36 Precuneus 31
3.17 0.001 0.65 −26 −82 34 Cuneus 19
0 303 5.14 < 0.001 1.05 32 −73 44 Superior Parietal 7
4.46 < 0.001 0.91 32 −78 36 Precuneus 39
4.12 < 0.001 0.84 28 −67 38 Precuneus 7
0 1710 5.11 < 0.001 1.04 0 41 0 Anterior Cingulate 32
4.93 < 0.001 1.01 3 24 19 Anterior Cingulate 24
4.54 < 0.001 0.93 10 51 12 Medial Frontal 10
0 730 4.97 < 0.001 1.01 −40 −9 −3 Insula 13
4.54 < 0.001 0.93 −38 −9 −14 Angular gyrus 39
4.51 < 0.001 0.92 −57 −30 13 Superior Temporal 22
0.02 98 4.89 < 0.001 1.00 −54 −61 −15 Fusiform 37
0 416 4.74 < 0.001 0.97 51 6 −5 Superior Temporal 22
4.51 < 0.001 0.92 45 −10 7 Insula 13
4.36 < 0.001 0.89 39 −16 7 Insula 13
0 176 4.7 < 0.001 0.96 −60 −39 21 Superior Temporal 22
4.35 < 0.001 0.89 −51 −36 16 Superior Temporal 22
0 218 4.69 < 0.001 0.96 −32 56 1 Middle Frontal 10
4.35 < 0.001 0.89 −16 60 1 Superior Frontal 10
3.95 < 0.001 0.81 −24 53 9 Middle Frontal 10
0 2357 4.66 < 0.001 0.95 6 −33 28 Cingulate 23
4.55 < 0.001 0.93 −9 −70 36 Precuneus 7
4.52 < 0.001 0.92 −3 −55 28 Cingulate 31
0 456 4.6 < 0.001 0.94 −42 3 4 Insula 13
4.49 < 0.001 0.92 −39 15 −9 Inferior Frontal 47
4.03 < 0.001 0.82 −36 23 −8 Inferior Frontal 47
0.003 138 4.51 < 0.001 0.92 −21 −40 −3 Parahippocampal 19
4.02 < 0.001 0.82 −33 −40 −11 Fusiform 36
0 529 4.46 < 0.001 0.91 36 20 1 Insula 13
4.16 < 0.001 0.85 44 24 0 Inferior Frontal 47
3.9 < 0.001 0.80 36 9 0 Insula 13
0 316 4.46 < 0.001 0.91 32 59 −2 Superior Frontal 10
4.4 < 0.001 0.90 22 63 6 Middle Frontal 10
3.85 < 0.001 0.79 28 60 10 Middle Frontal 10
0 338 4.38 < 0.001 0.89 60 −19 13 Transverse Temporal 42
4.13 < 0.001 0.84 48 −25 12 Transverse Temporal 42
3.66 < 0.001 0.75 57 −13 9 Superior Temporal 22
0 230 4.37 < 0.001 0.89 −51 −55 42 Inferior Parietal 40
4.21 < 0.001 0.86 −48 −63 40 Inferior Parietal 40
3.8 < 0.001 0.78 −44 −70 39 Precuneus 39
0.033 89 4.3 < 0.001 0.88 2 −58 49 Precuneus 7
0.042 85 4.28 < 0.001 0.87 51 11 22 Inferior Frontal 44
0.001 167 4.14 < 0.001 0.85 27 50 13 Middle Frontal 10
4.1 < 0.001 0.84 28 50 24 Superior Frontal 10
0.001 158 4.1 < 0.001 0.84 −12 17 −2 Caudate 48
3.59 < 0.001 0.73 −14 9 10 Caudate 48
0.001 149 4.06 < 0.001 0.83 −8 56 0 Medial Frontal 10
4.03 < 0.001 0.82 −8 62 −15 Medial Frontal 11
3.84 < 0.001 0.78 −4 65 −5 Medial Frontal 10
0.024 95 3.96 < 0.001 0.81 −60 −13 −32 Inferior Temporal 20
3.43 < 0.001 0.70 −51 −9 −29 Inferior Temporal 20
3.39 < 0.001 0.69 −57 −7 −36 Inferior Temporal 20
0.033 89 3.81 < 0.001 0.78 −33 −49 40 Angular gyrus 39
0.03 91 3.59 < 0.001 0.73 12 15 −2 Caudate 48
3.53 < 0.001 0.72 16 21 1 Caudate 48
3.43 < 0.001 0.70 10 11 6 Caudate 48
ApoE ε4 Non-carrier SUVR at 72month < SUVR at 0month
0 312 4.35 < 0.001 0.89 54 −39 −11 Medial temporal 21
4.11 < 0.001 0.84 52 −48 6 Medial temporal 37
4.01 < 0.001 0.82 60 −37 −3 Medial temporal 21
0.003 174 3.96 < 0.001 0.81 −2 −72 28 Precuneus 31
3.78 < 0.001 0.77 −6 −72 21 Cuneus 18
3.45 < 0.001 0.70 0 −72 37 Precuneus 31
0.006 157 3.9 < 0.001 0.80 58 −19 −18 Inferior Temporal Gyrus 21
3.76 < 0.001 0.77 57 −12 −21 Inferior Temporal Gyrus 21
3.72 < 0.001 0.76 58 −12 −11 Middle Temporal Gyrus 21
0.014 135 3.77 < 0.001 0.77 −3 −46 7 Posterior Cingulate 30
(continued on next page)
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up interval and atrophy as these variables were controlled for in our
analyses. Overall, by taking a longitudinal approach and correcting for
partial volume eﬀects, our study elucidates an ApoE ε4-related meta-
bolic pattern in MCI patients.
The vast majority of previous studies linking the ApoE ε4 genotype
to age-related decreases in cerebral glucose metabolism and blood ﬂow
have not been in patients with MCI (Breslow et al., 1982; Farrer et al.;
Scarmeas et al., 2004; Thambisetty et al., 2010a; Wolk and Dickerson,
2010). For example, Thambisetty et al. found greater longitudinal de-
cline in cerebral blood ﬂow in non-demented ApoE ε4 carriers com-
pared to non-carriers in the temporal, parietal, and frontal cortices
(Thambisetty et al., 2010a). Consistent with a blood ﬂow decrease of
−6% to −2% in ApoE ε4 carriers compared to non-carriers in their
study, we also observe similar regional decreases in FDG uptake in ε4
carriers compared to non-carriers in patients with MCI. Drzezga com-
pared FDG uptake in ApoE ε4 carriers to non-carriers with Alzheimer's
and found a pattern of cerebral hypometabolism in the parietal, tem-
poral, and cingulate cortical areas in ApoE ε4 carriers compared to non-
carriers (Drzezga et al., 2005). In the context of MCI, we ﬁnd, in ad-
dition to the temporal cortex, parietal cortex, and posterior cingulate,
previously unreported ApoE ε4-associated metabolic eﬀects in the
caudate, putamen, and amygdala. The ApoE ε4 allele has been pre-
viously shown to induce amygdalar atrophy in the context of MCI and
AD but has been not reported to change metabolic status in either MCI
or AD (Tang et al., 2015). Likewise, distinct patterns of striatal atrophy
and increased Aβ deposition, but not metabolic change, have been
observed in ApoE ε4 carriers compared to non-carriers in Alzheimer's
disease (Cohen and Klunk, 2014; Pievani et al., 2013). By taking a
longitudinal approach, we were able to elucidate previously unreported
metabolic changes in the limbic region and striatum of ApoE ε4 carriers
compared to non-carriers with MCI. A paired t-test assessing voxel-wise
FDG at 72months and 0months complement the results of the more
extensive longitudinal mixed-eﬀects ROI-based modeling (Tables 2, 3).
Our ﬁndings, combined with existing data showing the increased power
of incorporating ApoE ε4 carrier status in predicting conversion from
MCI to AD, underscore the importance of studying the metabolic eﬀects
of the ApoE ε4 allele speciﬁcally among individuals with MCI.
While previous studies have explored ApoE ε4-dependent changes
in subjects with AD and MCI, these studies have largely been cross-
sectional (Drzezga et al., 2005; Hirono et al., 2002; Matsuda, 2001;
Reiman et al., 1996; Roher et al., 2012; Scarmeas et al., 2004). Long-
itudinal studies are powerful in their ability to assess pathological
changes over time rather than at a single time point. Diﬀerences in
participant survival rates and changes in PET imaging measurement
over time lead to variable FDG SUVR values. As a result, apparent ApoE
ε4-mediated decreases in FDG SUVR at any given time point may not be
Table 3 (continued)
Cluster level Peak level
MNI Coordinatesb
3.75 < 0.001 0.77 0 −60 15 Posterior Cingulate 31
Results of the paired t-test comparing 72month and matched baseline FDG scans in SPM are presented in Table 3. Among ApoE ε4 carriers, we found 23 clusters
(cluster level FWER<0.05; peak level uncorrected p < .001) in which FDG at 72months< 0months. Among ApoE ε4 non-carriers, we found 4 signiﬁcant clusters
after cluster-level correction.
a Cluster p value was corrected for FWER using SPM12.
b Coordinates are in MNI space based on the output from SPM12.
c MNI coordinates were mapped to the nearest gray matter brain region and Brodmann area using Talairach Client (v2.4.3; talairach.org).
Fig. 2. Representative single-subject SUVR images with PVC at baseline and 72months. PVC-based FDG SUVR images at baseline and 72-month scans from two ApoE
ε4 carriers and two non-carriers are displayed in MNI standard-space. The scans demonstrate typical longitudinal changes in FDG signal over the study period and
conﬁrm the results pooled voxel-wise results (Fig. 3).
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statistically signiﬁcant. Longitudinal studies overcome this challenge by
considering patterns of tracer uptake over time. To our knowledge, our
work represents the longest lasting longitudinal study on ApoE ε4 de-
pendent changes in MCI.
To minimize partial volume eﬀects in FDG SUVR measurements
resulting from low image resolution in PET images from this multi-site
collaboration, we applied PVC using previously published methods
(Tohka and Reilhac, 2008). Poor image resolution can lead to blurring
of images and subsequent spill-out or spill-in of tracer signal into sur-
rounding regions determined by a point spread function. We applied a
deconvolution based partial volume correction to adjust for these ef-
fects. Our ROI based results conﬁrm that the PVC is necessary to elu-
cidate ApoE ε4-mediated changes in FDG uptake in small regions.
Speciﬁcally, we observe a near but not signiﬁcant ApoE ε4-mediated
eﬀect in FDG uptake in the superior frontal cortex and amygdala
(p= .065, 0.094 for superior frontal and amygdala, respectively)
without PVC for patients with MCI. However, after correcting for the
partial volume eﬀect, we observed a signiﬁcant ApoE ε4-mediated ef-
fect in these regions. Similarly, using a paired t-test voxelwise analysis,
we observed fewer signiﬁcant clusters in which FDG at 72month< 0
month in both the ApoE ε4 carrier group (23 clusters with PVC and 14
clusters without PVC) and ApoE ε4 non-carrier group (4 clusters with
PVC and 0 clusters without PVC). Both the ROI-based and voxelwise
ﬁndings underscore the importance of correcting for partial volume
eﬀects for accurate FDG measurement during longitudinal aging studies
involving atrophy of brain regions that are small relative to the PET
spatial resolution. Further, as a result of applying PVC, we are conﬁdent
that changes in FDG reported here are genuine metabolic changes as-
sociated with ApoE ε4 rather than due to volume-related or technical
biases.
As a limitation to our study, it should be noted that other patholo-
gies, such as intraneuronal protein deposits and cerebrovascular dis-
ease, may explain diﬀerences in glucose hypometabolism between
ApoE ε4 carriers and non-carriers in our study. For example, white
matter hyperintensities, or areas of increased T2-MRI signal due to
small vessel cerebrovascular disease, have previously been shown to
contribute to glucose metabolism in AD (Prins and Scheltens, 2015;
Tosto et al., 2015). Baseline diﬀerences in cerebrovascular disease be-
tween ApoE ε4 carriers and non-carriers in our cohort may partially
explain diﬀerences in glucose hypometabolism. Likewise, neuroﬁ-
brillary tangles, composed of intracellular deposits of tau protein, and
extracellular beta-amyloid plaques can occur before the onset of
Fig. 3. Voxelwise statistical analysis of PVC based FDG SUVR
longitudinal changes in ApoE ε4 carriers and non-carriers.
MNI152 standard-space T1-weighted average structural tem-
plate overlay showing voxels with signiﬁcant decrease in FDG
at 72months compared to baseline (cluster-level correction:
FWER<0.05; voxel uncorrected p < .001). Overlay ﬁgures
were generating by performing a paired t-test comparing
72month PVC scans with matched baseline PVC scans in SPM
separately for ApoE ε4 carriers (left) and non-carriers (right).
Fig. 4. Typical single-subject FDG-PET Image with PVC and non-PVC. Representative cross-sectional slices from selected ApoE ε4 carriers (subject ID: 041_S_1418)
and non-carriers (subject ID: 033_S_0906) with and without PVC are displayed to demonstrate the eﬀect of PVC at the single-subject level.
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cognitive symptoms and have been shown to promote glucose hypo-
metabolism in AD (Beason-Held et al., 2013; Bischof et al., 2016;
Ingelsson et al., 2004). Because only 56% of our study participants had
baseline amyloid (CSF and amyloid imaging) data available, we were
unable to control for baseline amyloid positivity. As a result, diﬀerences
in the severity of amyloid beta and tau proteinopathy between ApoE ε4
carriers and non-carriers in our cohort may lead to observed diﬀerences
in hypometabolism.
Due to limited sample size, a lack of sex and ApoE ε4 subtype ((ε4/
ε4), (ε4/ ε2), and (ε4/ ε3)) speciﬁc analysis is a further limitation to our
study. Indeed, recent studies have found sex-speciﬁc diﬀerences in AD
biomarkers and pathologic changes in MCI and AD (Holland et al.,
2013; Hua et al., 2010; Lin et al., 2015; Skup et al., 2011; Sundermann
et al., 2017). To avoid potential confounding due to sex, we included
sex as a covariate in all of our analyses. Future studies may focus on
analyzing sex-speciﬁc associations between the ApoE ε4 allele and FDG-
PET in MCI. Human and transgenic mice experiments have consistently
shown diﬀerences in AD risk and biomarker levels between subjects
with ε4, ε3, and ε2 alleles (Liu et al., 2013). Notably, the ApoE ε2 allele
has been previously shown to have a neuroprotective eﬀect in Alzhei-
mer's disease (Corder et al., 1994). As the ADNI cohort sample in-
creases, we hope to investigate ApoE ε4 subtype-speciﬁc eﬀects on
longitudinal FDG uptake in MCI and AD patients in future studies.
It should also be noted that our cohort selection method used cog-
nitive staging and not biomarker proﬁles. The new NIA-AA research
framework regards Alzheimer's disease as a continuum with biomarker
proﬁle and cognitive staging as independent sources of information
(Jack et al., 2018). To accurately identify where on this continuum our
study participants are, biomarkers, such as Aβ 1–42, CSF tau,
[18F]AV1451 PET, [11C]PIB PET, and [18F]AV45, must be proﬁled. A
biomarker-based deﬁnition of AD helps us move away from deﬁning AD
as a clinical syndrome with or without evidence of neuropathologic
change towards a biological disease marked by distinct biomarker
changes. However, given that we are limited by the lack of available
biomarkers in ADNI, our cohort should more accurately be described as
participants with a clinical deﬁnition of MCI rather than a biological
one.
5. Conclusion
We assessed the eﬀect of the ApoE ε4 allele on glucose metabolism
in MCI and elucidated a novel, regional pattern of glucose hypometa-
bolism over up to 84-months longitudinal follow-up period
(median= 72months). Speciﬁcally, the superior fontal, parietal, lateral
temporal, medial temporal, caudate, thalamus, and post-cingulate, and
amygdala regions show greater longitudinal decreases in FDG uptake in
ApoE ε4 carriers compared to non-carriers in the context of MCI. Partial
volume correction improved quantitative FDG PET sensitivity in the
study. Overall, our work represents one of the longest FDG studies of
MCI, and uncovers a novel ApoE ε4-associated metabolic dynamic
pattern in patients with MCI.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nicl.2019.101795.
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